Abcuro is a clinical stage biotechnology company developing treatments for autoimmune and cancer indications modulated by cytotoxic T and NK cells that express the inhibitory immune checkpoint receptor KLRG1 (killer cell lectin-like receptor G1). The company is advancing ABC008, a first-in-class anti-KLRG1 antibody designed to deplete cytotoxic T cells that attack healthy muscle tissue in patients with inclusion body myositis (IBM), into clinical studies.

Biotechnology

Abcuro

Abcuro's headquarters in Newton, MA, United States

Alex Martin

Jeff Geary

Bill Yates

Daniel Mansuri

Ricky Motschwiller

Donna Byrne

Mike Gress

Karen Tubridy

Hugo Lemessurier

Dave Borbas

H. Jeffrey Wilkins, MD

Rajeev Shah

Steven A Greenberg

Jay Knowles

Jason P. Hafler

Tomer Kariv

Dietmar Berger

Yajun Xu

Jonah Cashdan

Ming Fang

Mark Pruzanski

Mike Dybbs

Description

People (11)

Steven A Greenberg

LaDonna Hoffer

Dulce Soler-Ferran

Ricky Motschwiller

Brett Chartienitz

Johnny Pepen

Jeff Geary

Eileen Brennan

Sam Sundaram

Fang Han

Rajesh P

Jobs